Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Peto, A.D. López, J. Boreham, M. Thun, C. Heath.
Mortality from tobacco in developed countries: indirect estimation from national stadistics.
Lancet, 339 (1992), pp. 1268-1278
[2.]
L.M. Ramstrom.
Prevalence and other dimensions of smoking in the world.
pp. 64-77
[3.]
J.H.A. Prabhat, F.J. Chaloupka, P. Brown, S. Nguyen, J. Severino-Márquez, R. Van der Merwe, et al.
Curbing the epidemic.
Governments and the economics of tobacco control,
[4.]
Centers for Disease Control and Prevention.
State specific prevalence of cigarrette smoking among adults and children's and adolescents' exposure to environmental tobacco smoke-United States, 1996.
Mmwr, 46 (1997), pp. 1038-1043
[5.]
J. Muñiz.
Consumo de tabaco en la población española.
Libro Blanco sobre el Tabaquismo en España. Comité Nacional para la Prevención del Tabaquismo, pp. 15-30
[6.]
A. Pérez Trullén, R. Marrón.
Guías prácticas de deshabituación tabáquica: ¿qué son, por qué y cómo utilizarlas?.
Arch Bronconeumol, 35 (1999), pp. 84-88
[7.]
C. Jiménez, S. Solano, J.M. González de Vega, M.J. Ruíz, A. Ramos, M. Barrueco, et al.
Tratamiento del tabaquismo.
Recomendaciones SEPAR, pp. 421-436
[8.]
J.R. Hughes, S. Fiester, M.G. Goldstein, M.P. Resnick, N. Rock, D. Ziedonis.
American Psychiatric Association pratice guideline for the treatment of patients with nicotine dependence.
Am J Psychiatry, 153 (1996), pp. S1-S31
[9.]
M.C. Fiore, W.C. Bailey, S.C. Cohen, et al.
Smoking cessation: clinical practice guideline, n.° 18,
[10.]
M. Raw, A. McNeill, R. West.
Smoking cessation guidelines for health professionals: a guide to effective smoking cessation interventions.
Thorax, 52 (1998), pp. S1-S19
[11.]
S. Parrot, C.h. Godfrey, M. Raw, R. West, A. McNeill.
Guidance for commissioners on the cost-effectiveness of smoking cessation interventions.
Thorax, 52 (1998), pp. S1-S39
[12.]
A. Pérez Trullén, L. Clemente.
¿Cómo ayudar a sus pacientes a dejar de fumar?,
[13.]
A. Pérez Trullén.
Naturaleza del humo del tabaco: farmacología de la nicotina.
Arch Bronconeumol, 31 (1995), pp. 101-108
[14.]
A. Pérez Trullén, L. Clemente, J.M. Carreras, R. Marrón, E. Rubio, C. Montañés.
Tratamiento farmacológico del tabaquismo con sustitutivos de la nicotina.
Aten Farm (Eur J Clin Pharm), 1 (1999), pp. 252-262
[15.]
A. Bayot.
Eficacia de la farmacoterapia en la eliminación del tabaquismo.
Rev Esp Drogodep, 20 (1995), pp. 177-196
[17.]
O. Ferno, S. Lichtneckert, E. Lundgren.
A substitute for tobacco smoking.
Psychopharmacology, 31 (1973), pp. 201-204
[18.]
L. Clemente, A. Pérez Trullén, J.M. Carreras.
Tratamiento farmacológico del tabaquismo.
Fmc, 5 (1998), pp. 329-336
[20.]
C. Sylagy, D. Mant, G. Fowler, T. Lancaster.
Cochrane Tobacco Addiction Group. The Cochrane database of systematic reviews.
The Cochrane Library issue 3, (2000),
[21.]
M.J. Jarvis, M.A.H. Russell.
Treatment for the cigarrette smoker.
Int Rev Psychiatr, 1 (1989), pp. 139-147
[22.]
V. Baos.
Guía de uso de los medicamentos en Atención Primaria,
[23.]
H. Pardell, E. Saltó, L.L. Salleras.
Manual de diagnóstico y tratamiento del tabaquismo,
[24.]
P. Tonnesen, V. Frid, M. Henisen.
Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking.
N Engl J Med, 318 (1988), pp. 15-18
[25.]
J. Hughes, D. Hatsukami, Skoggk.
Physical dependence on nicotine gum.
Jama, 255 (1986), pp. 3277-3279
[26.]
J. Hughes, D. Hatsukami.
Sing and symptoms of tobacco withdrawal.
Arch Gen Psychiatr, 43 (1986), pp. 289-294
[27.]
R. West, M. Jarvis, M. Rusell, M. Carruthers, C. Feyerabend.
Effects of nicotine replacement on the cigarette withdrawal syndrome.
Br J Addict, 79 (1984), pp. 215-219
[28.]
J.R. Hughes, M.G. Goldstein, R.D. Hurt, S. Shiffman.
Recent advances in the pharmacotherapy of smoking.
Jama, 281 (1999), pp. 72-76
[29.]
P. Hayek, P. Jackson, M. Belchen.
Long term use of nicotine chewing gum.
Jama, 260 (1988), pp. 1593-1596
[30.]
R.D. Hurt, L.C. Dale, F.L. McClain, K.M. Eberman, K.P. Offord, B.K. Bruce, et al.
A comprehensive model for the treatment of nicotine dependence in a medical setting.
Med Clin North Am, 76 (1992), pp. 495-514
[31.]
K. Fagerström.
Efficacy of nicotine chewing gum: a review.
Nicotine replacement in the treatment for smoking, pp. 109-128
[32.]
W. Lam, P.C. Sze, H.S. Sacks, T.C. Chalmers.
Meta-analisis of randomised controlled trials of nicotine chewing-gum.
Lancet, 2 (1987), pp. 27-30
[33.]
C. Cabezas.
Deshabituación tabáquica, nuevas estrategias.
Fmc, 1 (1994), pp. 19-32
[34.]
R.E. Johnson, V.J. Stevens, J.F. Hollins, G.T. Woodson.
Nicotine chewing gum use in the outpatients care setting.
J Fam Pract, 34 (1992), pp. 61-65
[35.]
E. Monsó, A. Rosell, E. Pujol, J. Ruiz, A. Fabregat, J. Morera.
Intervención mínima sobre tabaquismo en la consulta neumológica extrahospitalaria.
Arch Bronconeumol, 30 (1994), pp. 12-15
[36.]
T. Abelin, A. Buehler, P. Muller, K. Vesanen, P. Lmhof.
Controlled trial of transdermal nicotine patch in tobacco withdrawal.
Lancet, 1 (1989), pp. 7-10
[37.]
D.M. Daughton, S.A. Heatly, J.J. Predergast, et al.
Effect of transdermal nicotine delivery as an adjunt to low intervention smoking cessation a randomized, placebo-controlled double-blind study.
Arch Intern Med, 151 (1991), pp. 749-752
[38.]
Transdermal Nicotine Study Group.
Transdermal nicotine for smoking cessation: six month results from two multicenter controlled clinical trials.
Jama, 266 (1991), pp. 3133-3138
[39.]
M.C. Fiore, D.E. Jorenby, T. Baker, S.L. Kenfor.
Tobacco dependence and the nicotine patch, clinical guidelines for effective use.
Jama, 268 (1992), pp. 2687-2694
[40.]
M.C. Fiore, S.S. Smith, D.E. Jorenby, T.B. Baker.
The effectiveness of the nicotine patch for smoking cessation.
Jama, 271 (1994), pp. 1940-1947
[42.]
M.G. Sneider.
Nicotine therapy in smoking cessation pharmacokinetic considerations.
Clin Pharmacokinet, 23 (1992), pp. 169-172
[43.]
N.G. Schneider, R. Olmstead, F.V. Mody, et al.
Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double- blind trial.
Addiction, 90 (1995), pp. 1671-1682
[44.]
T. Blondal, M. Franzon, A. Westin.
A double blind randomized trial of nicotine nasal spray as an aid in smoking cessation.
Eur Respir J, 10 (1997), pp. 1585-1590
[45.]
G. Sutherland, J.A. Stapleton, M.A.H. Russel, et al.
Randomised controlled trial of nasal nicotine spray in smoking cessation.
Lancet, 340 (1992), pp. 324-329
[46.]
M.A. Russell, M.J. Jarvis, C. Feyerabend, O. Ferno.
Nasal nicoine solution. A potencial aid to giving up smoking?.
Br Med J, 286 (1983), pp. 683-684
[47.]
M. Russell, Jarvis, G. Devitt, C. Feyeranbend.
Nicotine intake by snuff users.
Br Med J, 283 (1981), pp. 814-817
[48.]
C. Sylagy, D. Mant, G. Fowler, M. Lodge.
Metaanalysis on efficacy of nicotine replacement therapies in smoking cessation.
Lancet, 343 (1994), pp. 139-142
[49.]
J.A. Stapleton, G. Sutherland, M. Russell.
How much does relapse after one year erode effictiveness of smoking cessation treatments? Long term follow up of randomised trial of nicotine nasal spray.
Br Med J, 316 (1998), pp. 830-831
[50.]
D.W. Sepkivic, S.G. Colosimo, C.M. Axellrad, J.D. Adams, M.J. Halley.
Delivery and uptake of nicotine from aerososl rod.
Am J Public Health, 76 (1986), pp. 1343-1413
[51.]
M.A.H. Russell, M. Jarvis, G. Sutherland, C. Feyerabend.
Nicotine remplacement in smoking cessation: absorption of nicotine from smoke-free cigarettes.
Jama, 257 (1987), pp. 3262-3265
[52.]
A. Hjalmarson, F. Wilsson, L. Sjostrom, et al.
The nicotine inhaler in smoking cessation.
Arch Intern Med, 157 (1997), pp. 1721-1728
[53.]
W.D. Schneider, R. Olmstead, F. Wilsson, et al.
Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial.
Addiction, 91 (1996), pp. 1293-1306
[54.]
P. Tonnesen, J. Norregaard, K. Mikkelsen, S. Jorgensen, F. Nilson.
A double blind of a nicotine inhaler for smoking cessation.
Jama, 269 (1993), pp. 1268-1271
[55.]
Pharmacia and Upjohn.
Summary of product characteristic for nicorette sublingual tablet 2 mg, (1998),
[56.]
M. Wallstrom, F. Nilsson, J.M. Hirsch.
A double-blind, placebo controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation.
Eur Respir, 10 (1997), pp. 440
[57.]
Westman EC, Tomlin KF, Perkins Ch, Rose JE. Oral nicotine solution: a pilot study for smoking cessation. Duke and Durhan VA Medical Center Nicotine Research Program, and Departments of Medicine and Psichiatry, Duke University Medical Center. Durham North Carolina. www.globalink.org.
[58.]
L. Clemente, A. Pérez Trullén, J.M. Carreras, R. Marrón, et al.
Tratamientos farmacológicos del tabaquismo no nicotínicos.
Aten Farm (Eur J Clin Pharm), 1 (1999), pp. 357-367
[59.]
J.L. Dorsey.
Control of the tobacco habit.
Ann Intern Med, 10 (1936), pp. 628-631
[60.]
L.S. Covey, M.A. Sullivan, J.A. Johnston, A.H. Glassman, M.D. Robinson, D.P. Adams.
Advances in non-nicotine pharmacotherapy for smoking cessation.
Drugs, 59 (2000), pp. 17-31
[61.]
W. Emmet, M.D. Lee, E. Gilbert, D.O. D'Alonzo.
Cigarette smoking, nicotine addiction, and pharmacologic treatment.
Arch Intern Med, 153 (1993), pp. 34-48
[62.]
J. Flórez, J.A. Armijo, A. Mediavilla.
Farmacología humana,
[63.]
J.R. Sáenz, H. Esparza.
Inf Ter Sist Nac Salud, 18 (1994), pp. 125-133
[65.]
A. Martínez.
Patología del consumo de tabaco,
[66.]
Consejo General de Colegios Oficiales Farmacéuticos.
Guía de prescripción. Madrid, (1995),
[67.]
J. Grabowski, S.M. Hall.
Pharmacological adjuncts in smoking cessation, pp. 1-13
[68.]
Health and Public Policy Committee.
American College of Physicians. Methods for stopping cigarette smoking.
Ann Intern Med, 105 (1986), pp. 281-291
[69.]
N.L. Benowitz, M.W. Peng.
Non-nicotine pharmacotherapy for smoking cessation: mechanisms and prospects.
CNS Drugs, 13 (2000), pp. 265-285
[70.]
A.H. Glassman, W.K. Jackson, B.T. Walsh, S.P. Roose.
Cigarette craving, smoking withdrawal, and clonidine.
Science, 226 (1982), pp. 864-866
[71.]
J.R. Hughes.
Clonidine, depression, and smoking cessation.
Jama, 259 (1988), pp. 2901-2902
[72.]
S.A. Ornish, S. Zisook, L.A. McAdams.
Effects of transdermal clonidine treatment on symptoms associated with smoking cessation: a randomized, controlled trial.
Arch Intern Med, 148 (1988), pp. 2027-2031
[74.]
K.O. Fagerström.
Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment.
Addict Behavior, 3 (1978), pp. 235-241
[75.]
A.H. Glassman, F. Stetner, T. Wals, et al.
Heavy smokers, smoking cessation, and clonidine.
Jama, 259 (1988), pp. 2863-2866
[76.]
L.S. Covey, A.H. Glassman.
A meta-analysis of double blind placebo- controlled trials of clonidine for smoking cessation.
Br J Addict, 86 (1991), pp. 991-998
[77.]
K.L. Sees, S.A. Stalcup.
Combining clonidine and nicotine replacement for treatment of nicotine withdrawal.
J Psychoactive Drugs, 21 (1989), pp. 355-359
[78.]
F.S. Tennant, A.L. Tarver.
Withdrawal from nicotine using mecamylamine: comparison of three-week and six-week dosage schedules.
Problems of drug dependence, pp. 291-297
[79.]
I.P. Stoleman.
Could nicotine antagonists be used in smoking cessation?.
Br J Addict, 81 (1986), pp. 47-53
[80.]
F.S. Tennant, A.L. Tarver, R.A. Rawson.
Clinical evaluation of mecamylamine for nicotine dependence, pp. 239-246
[81.]
J.E. Rose, F.M. Behm, E.C. Westham, et al.
Mecamylamine combined with nicotine sking patch facilitates smoking cessation beyond nicotine patch treatment alone.
Clin Pharmacol Ther, 56 (1994), pp. 86-99
[82.]
J.E. Rose, E.D. Levin.
Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence.
Pharmacol Biochem Behav, 41 (1991), pp. 219-226
[83.]
M.A.H. Russell, M.J. Jarvis.
Theoretical background and clinical use of nicotine chewing gum.
Pharmacological adjuncts in smoking cessation. Bethesda, NIDA, Monograph 53,, pp. 110-130
[84.]
R.M. Glass.
Blue mood, blackened lungs: depression and smoking.
Jama, 264 (1990), pp. 1583-1584
[85.]
S.M. Hall, R. Muñoz, V. Reus.
Smoking cessation, depression and dysphoria.
NIDA Res Monograph, 105 (1991), pp. 313-323
[86.]
K.J. Holm, C.M. Spencer.
Bupropion: a review of its use in the management of smoking cessation.
Drugs, 59 (2000), pp. 1-14
[87.]
R.D. Hurt, D.P.L. Sachs, E.D. Glover, et al.
A comparison of sustained- realase bupropion and placebo for smoking cessation.
N Engl J Med, 337 (1997), pp. 1195-1202
[88.]
L.H. Ferry, R.J. Burchette.
Efficacy of bupropion for smoking cesssation in non-depressed smokers.
J Addict Dis, 13 (1994), pp. 249
[89.]
Anfebutamona para dejar de fumar.
Med Letter (ed. esp), 20 (1997), pp. 89-90
[90.]
J.A. Ascher, J.O. Cole, J.N. Colin, et al.
Bupropion a review of its mechanisms of antidepresant activity.
J Clin Psychiatr, 56 (1995), pp. 395-401
[91.]
Physicians Desk Reference, 51.a,
[92.]
H.I. Lief.
Bupropion treatment of depression to assist smoking cessation.
Am J Psychiatr, 153 (1996), pp. 442
[93.]
A.H. Glassman, J.E. Helzer, L.S. Covey, et al.
Smoking, smoking cessation, and major depression.
Jama, 264 (1990), pp. 1546-1549
[94.]
J.R. Hughes.
Dependence potencial and abuse liability of nicotine replacement therapies.
pp. 277
[95.]
R.A. Wise.
Brain neuronal systems mediating reward processes.
Neurobiology of optate reward mechanisms, pp. 405-438
[96.]
A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor.
Goodmand and Gilman's the pharmacological casis of therapeutics, 8.a,
[97.]
G. Di Chiara, A. Imperato.
Drugds abuse by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci USA, 85 (1988), pp. 5274-5278
[98.]
P.B. Clarke.
Nicotine dependence-mechanisms and therapeutic strategies.
Biochem Soc Symp, 59 (1993), pp. 83-95
[99.]
J.S. Fowler, N.D. Volknow, G.J. Wang, et al.
Inhibition of monoamine oxidase B in the brains of smokers.
Nature, 379 (1996), pp. 733-737
[100.]
D.E. Jorenby, S.J. Leischow, M. Nide, et al.
A controlled tiral of sustained-release bupropion, a nicotine patch or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[101.]
R.M. Ferris, B.R. Cooper.
Mechanism of antidepressant activity of bupropion.
J Clin Psychiatr Monogr, 11 (1993), pp. 2-14
[102.]
M.C. Fiore, S.S. Smith, D.E. Jorenby, T.B. Baker.
The effectiveness of the nicotine patch for smoking cessation.
Jama, 271 (1994), pp. 1940-1947
[103.]
R.C. Klesges, G.W. Somes, R. Pascale, et al.
Knowledge and beliefs regarding the consequences of cigarette smoking and their relationships regarding to smoking status in a biracial ample.
Health Psychol, 7 (1988), pp. 387-401
[104.]
L.S. Covey, A.H. Glassman, F. Stetner.
Depression and depresive symptoms in smoking cessation.
Compro Psychiatr, 31 (1990), pp. 350-354
[105.]
S. Shiffman.
Relapse following smoking cessation: a situational analysis.
J Consult Clin Psychol, 50 (1982), pp. 71-86
[107.]
K. Nielsen, M.C. Fiore.
Cost-benefit analysis of sustained-release bupropion, nicotine patch or both for smoking cessation.
Pred Med, 30 (2000), pp. 209-216
[108.]
A. Pérez Trullén, L. Sánchez Agudo.
Guías prácticas de deshabituación tabáquica: ¿análisis coste-efectividad?.
Arch Bronconeumol, 35 (1999), pp. 89-94
[109.]
G. Humfleet, S. Hall, V. Reus, K. Sees, R. Muñoz, E. Triffleman.
The efficacy of nortriptyline as an adjunct to psychological treatment for smokers with and without depression histories.
Problems of drug dependence 1995: proceedings of the 57 th Annual Scientific Meeting, of the College on Problems of Drug Dependence, Inc. NDA Res Monogr 162,
[110.]
A.V. Prochazcka, M.J. Weaver, R.T. Keller, et al.
A randomized trial of northriptyline for smoking cessation.
Arch Intern Med, 158 (1998), pp. 2035-2039
[112.]
N.B. Edwards, J.K. Murphy, A.D. Downs, B.J. Ackerman, T.L. Rosenthal.
Doxepin as an adjunct to smoking cessation: a double-blind pilot study.
Am J Psychiatr, 146 (1989), pp. 373-376
[113.]
N.B. Edwards, R.C. Simmons, T.L. Rosenthal, et al.
Doxepin in the treatment of nicotine withdrawal.
Psychosomatic, 29 (1988), pp. 203-206
[114.]
J.K. Murphy, N.B. Edwards, A.D. Downs, et al.
Effects of doxepin on withdrawal symptoms in smoking cessation.
Am J Psychiatr, 147 (1990), pp. 1353-1357
[115.]
R. Niaura, M.D. Goldstein, J. Depue, et al.
Fluoxetine, symptoms of depression and smoking cessation.
Ann Behav Med, 17 (1995), pp. 61
[116.]
B. Spring, J. Wuertman, R. Wurtman.
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
Am J Clin Nutr, 62 (1995), pp. 1181-1187
[117.]
J.S. Fowler, N.D. Volkow, G.J. Wang, et al.
Brain monoamine oxidase A inhibition in cigarette smokers.
Proc Natl Acad Sci, 93 (1996), pp. 14065-14069
[118.]
I. Berlin, S. Said, O. Spreux-Varoquaux, et al.
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy dependent smokers.
Clin Pharmacol Ther, 58 (1995), pp. 444-452
[119.]
D.P. Taylor.
Buspirone a new approach to the treatment of ansiety.
Fed Am Soc Exp Biol J, 2 (1988), pp. 2445-2452
[120.]
J.R. Hughes, S.T. Higgins, D.K. Hatsukami, et al.
Effects of abstinence from tobacco.
Research advances in alcohol and drug problems, pp. 317-398
[121.]
K. Rickels, E. Schweitzer, Y. Caanalosi, G. Case, H. Chung.
Long term treatment of ansiety and risk of withdrawal: prospective comparison of clorazepate and buspirone.
Arch Gen Psychiatr, 45 (1988), pp. 444-450
[122.]
R.E. Newton, J.D. Marunycz, M.T. Alderidge, M.J. Napoliello.
Review of the side effect profile of buspirone.
Am J Med, 80 (1986), pp. 17-21
[123.]
M.D. Robinson, Y.L. Pettice, W.A. Smith, E.A. Cederstrom, D.E. Sutherland, H. Dais.
Buspirone effect on tobacco withdrawal symtoms: a randomized placebo-controlled trial.
J Am Board Fam Pract, 5 (1992), pp. 1-9
[124.]
N.G. Schneider, R.E. Olmstead, C. Steimberg, K. Sloan, R.M. Daims, H.V. Brown.
Efficacy of buspirone in smoking cessation: a placebo controlled trial.
Clin Pharmacol Ther, 60 (1996), pp. 568-575
[125.]
D.E. Hilleman, S.M. Mohiuddin, M.G. Del Core, M.H. Sketch.
Effect of buspirone on withdrawal symptoms associated with smoking cessation.
Arch Intern Med, 152 (1992), pp. 350-352
[126.]
D.E. Hilleman, S.M. Mohiuddin, M.G. Delcore.
Comparison of fixed dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation.
J Clin Pharmacol, 34 (1994), pp. 22-24
[127.]
P.M. Cinciripini, L. Lapitsky, S. Seay, A. Wallfisch, W.J. Meyer, H. Van Vunakis.
A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and lowanxiety smokers.
J Clin Psychopharmacol, 15 (1995), pp. 182-191
[128.]
B.S. Fox, K.M. Kantak, M.A. Edwards.
Efficacy of a therapeutic cocaine vaccine in rodent models.
Natural Med, 2 (1996), pp. 1129-1132
[129.]
Y. Hieda, D.E. Keyler, J.T. Vandevoort, et al.
Active immunization alters the plasma nicotine in rats.
J Pharmacol Exp Ther, 283 (1997), pp. 1076-1081
[130.]
Keyler DE, Hieda Y, St Petre J et al. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine.
Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica
